Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Oncology · Breast Cancer Res Treat · 2026-11-14
Meta-analysisn = 2,627
Wu et al. Survival benefit of adding carboplatin to standard anthracycline-taxane chemotherapy in triple-negative breast cancer: an updated systematic review and meta-analysisEar, nose and throat · Head Neck · 2026-10-05
Meta-analysisn = 1,044
Rahim et al. Efficacy and Safety of Cisplatin Versus Carboplatin for Patients With Squamous Cell Carcinoma of Head and Neck: A Systematic Review and Meta-AnalysisOncology · JAMA · 2026-09-08
RCTn = 294
Zhou et al. Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical TrialOncology · Clin Cancer Res · 2026-07-17
RCTn = 49
Li et al. Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II TrialOncology · J Clin Oncol · 2026-07-13
Guidelinen = 147 publications
Lesnock et al. Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0Oncology · Lancet Oncol · 2026-07-01
RCTn = 174
Seefat et al. Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trialOncology · Lancet Oncol · 2026-06-15
RCTn = 624
Li et al. Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trialOncology · Ann Oncol · 2026-05-30
RCTn = 868
Kim et al. A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trialOncology · Gynecol Oncol · 2026-05-26
Secondary analysisn = 315
Kuroki et al. Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249Oncology · ESMO Open · 2026-03-19
RCTn = 150
Gong et al. A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancerOncology · J Clin Oncol · 2026-01-23
RCTn = 774
Gao et al. Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP TrialOncology · BMJ · 2025-12-23
RCTn = 808
Liu et al. Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trialOncology · J Clin Oncol · 2025-12-09
RCTn = 786 patients
Chen et al. Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III TrialOncology · ESMO Open · 2025-11-25
RCTn = 83
Kuemmel et al. Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study